A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma
暂无分享,去创建一个
N. Sasahira | Yu Takahashi | A. Kasuga | T. Okamoto | M. Takamatsu | Chinatsu Mori | Takashi Sasaki | Takafumi Mie | Takaaki Furukawa | Yuto Yamada | Tsuyoshi Takeda | M. Matsuyama | M. Ozaka | Y. Ono | Fumihiro Kawano | Y. Takahashi | T. Furukawa
[1] N. Sasahira,et al. Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery , 2020, Journal of hepato-biliary-pancreatic sciences.
[2] T. Fujii,et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.
[3] P. Chu,et al. Capecitabine-Induced Enteritis Leading to Small Bowel Obstruction. , 2019, Gastroenterology.
[4] Jeffrey W. Clark,et al. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX , 2019, Annals of surgery.
[5] T. Fujii,et al. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery , 2019, Annals of Surgical Oncology.
[6] Hai Hu,et al. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. , 2017, Annals of surgery.
[7] J. Windsor,et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[8] K. Takaori. "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria? , 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[9] R. Caruso,et al. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. , 2017, Surgical oncology.
[10] J. Schellens,et al. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines , 2016, Cancer Chemotherapy and Pharmacology.
[11] Masao Tanaka,et al. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. , 2016, European journal of cancer.
[12] J. Sanderson,et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.
[13] Gabriel L. Butterfield,et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. , 2014, Cancer research.
[14] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[15] R. Danesi,et al. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. , 2013, Pharmacogenomics.
[16] H. Ueno,et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Unno,et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery , 2013, Journal of hepato-biliary-pancreatic sciences.
[18] N. Sasahira,et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study , 2012, British Journal of Cancer.
[19] T. Itoi,et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) , 2012, Cancer Chemotherapy and Pharmacology.
[20] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[21] B. Lacarelle,et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity , 2010, Cancer Chemotherapy and Pharmacology.
[22] U. Amstutz,et al. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. , 2009, Pharmacogenomics.
[23] A. Oto,et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] M. Maeta,et al. Induction of diffuse necrotizing enterocolitis by anticancer chemotherapy , 1987, Gastroenterologia Japonica.
[25] A. Shah,et al. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. , 2007, Clinical colorectal cancer.
[26] P. Soulié,et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance , 2006, Molecular Cancer Therapeutics.
[27] R. Diasio,et al. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. , 2004, Clinical colorectal cancer.
[28] H. Joensuu,et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] H. Lenz,et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.
[30] A. B. Kuilenburg,et al. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency , 2003 .
[31] A. V. van Kuilenburg,et al. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. , 2003, Annals of clinical biochemistry.
[32] H. Groen,et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene , 2002, British Journal of Cancer.
[33] C. Zacker,et al. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. , 2000, The oncologist.
[34] S. Barni,et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients , 1997, Supportive Care in Cancer.
[35] H. Parnes,et al. Chemotherapy‐induced lactose intolerance in adults , 1994, Cancer.
[36] R. Diasio,et al. Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.
[37] H. Spiro,et al. Colonic Histologic Changes Induced by 5-Fluorouracil , 1962 .